ena-STUDY-INSTITUTE OF PATHOLOGY-13-10-2020-13:26:11:802-262
Combined CDK4/6 and MEK inhibition in refractory CDKN2A and NRAS mutant melanoma
Combined CDK4/6 and MEK inhibition in refractory CDKN2A and NRAS mutant melanoma